Cell BioEngines, Inc., founded in December 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' cell therapies as ‘drugs’.
Cell BioEngines’ competitive edge lies in transgene-free, scalable manufacturing of 'super donor' blood stem cells, combined with HLA-guided design for broad patient coverage.
We Develop Cell-based Products Both Within Our Company and Through Our Partner Company

Allows Diversified Development of Multiple Programs Spanning Several Large Therapeutic Markets

Next-Generation Blood Stem Cell Reprogramming Platform for Derived, HLA-Matched Therapeutics
Blood Stem Cell-derived Therapeutic Product Candidates for Oncology and Immune-related Applications
Albert Einstein
We are therapeutic area agnostic which allows us maximum flexibility to focus on advancing cutting-edge stem cell-derived therapeutics approaches in oncology and regenerative medicine.
Allows us to pursue a broad range of products and product candidates with high clinical and commercial potential. This broad and deep diversification lowers the time to development and overall risk profile of the company.
Low cost manufacturing enables us to act quickly to seize time-sensitive opportunities and provides us with a wider range of options from which to select the most ideal financial structure for each product.